Frontlight ResearchEarly access
CompletedPhase 3
A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
Key facts
- Who runs it
- Kowa Research Institute, Inc.
- Where
- Albuquerque, Ann Arbor, Blue Ash, Cleveland, Dallas, Fort Myers, Grand Rapids, Houston, Lexington, Los Angeles, Madison, New York, Omaha, Palm Beach Gardens, Palo Alto, Portland, Sacramento, San Antonio, West Fargo, and Wichita, United StatesSee the 21 sitesAlso in 5 other countries, 22 sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 110 people enrolled
- Started
- 11 May 2023
- Ended
- 24 Oct 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Ripasudil
- Placebo
- Record updated
- 22 January 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Is at least 18 years old at the screening visit (Visit 1)
- Has a diagnosis of FECD at Visit 1
- Meet all other inclusion criteria outlined in the Clinical Study Protocol
Who cannot take part
- Is a female subject of childbearing potential and any of the following is true:; is pregnant or lactating/breastfeeding, or; is not surgically sterile, not post-menopausal (no menses for the previous 12 months), or not practicing an effective method of birth control as determined by the Investigator (eg, oral contraceptives, double barrier methods, hormonal injectable or implanted contraceptives, tubal ligation, or partner with vasectomy)
- Meet any other exclusion criteria outlined in the Clinical Study Protocol
Where in United States
Also in 5 other countries, 22 sites
- Eye Associates of New Mexico - Albuquerque - NorthsideAlbuquerque, United States
- W Kellogg Eye CenterAnn Arbor, United States
- Cincinnati Eye Institute-1945 Cei DrBlue Ash, United States
- University Hospitals Cleveland Medical Center - 11100 Euclid AveCleveland, United States
- University of Texas Southwestern Medical CenterDallas, United States
- Gorovoy MD Eye SpecialistsFort Myers, United States
- Verdier Eye CenterGrand Rapids, United States
- Houston Eye AssociatesHouston, United States
- University of KentuckyLexington, United States
- Keck Hospital of USCLos Angeles, United States
- Macy Eye CenterLos Angeles, United States
- University of Wisconsin School of Medicine and Public HealthMadison, United States
- NYU Langone HealthNew York, United States
- Vance Thompson Vision - OmahaOmaha, United States
- Bascom Palmer Eye InstitutePalm Beach Gardens, United States
- Byers Eye Institute at StanfordPalo Alto, United States
- Devers Eye InstitutePortland, United States
- Sacramento Eye ConsultantsSacramento, United States
- R and R Eye Research, LLCSan Antonio, United States
- Vance Thompson Vision West FargoWest Fargo, United States
- Grene Vision Group-WichitaWichita, United States
About the trial
What the trial wants to find out
A study to assess the safety and efficacy of K-321 in participants with FECD after simultaneous cataract surgery and descemetorhexis.
The 2 groups in the trial
- K-321Treatment being tested
K-321 ophthalmic solution four times daily (QID) for 12 weeks followed by a two-week gradual dose taper phase and 38-week follow-up phase
Treatment: Ripasudil
- PlaceboPlacebo, for comparison
Placebo ophthalmic solution QID for 12 weeks followed by a two-week gradual dose taper phase and 38-week follow-up phase
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Subjects With Fuchs Endothelial Corneal Dystrophy
- Record updated
- 22 January 2026